OKYO — OKYO Pharma Income Statement
0.000.00%
Last trade - 00:00- $60.63m
- $61.42m
Annual income statement for OKYO Pharma, fiscal year end - March 31st, GBP millions except per share, conversion factor applied.
C2019 March 31st | 2020 March 31st | R2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 3.76 | 1.31 | 2.58 | 4.55 | 10.9 |
| Operating Profit | -3.76 | -1.31 | -2.58 | -4.55 | -10.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -3.76 | -1.27 | -2.58 | -4.55 | -11 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.76 | -1.21 | -2.56 | -3.98 | -11 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.76 | -1.21 | -2.56 | -3.98 | -11 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.76 | -1.21 | -2.56 | -3.98 | -11 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -28.6 | -8.14 | -16.1 | -0.264 | -0.495 |
| Dividends per Share |